Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-06-23
2011-10-11
Tsang, Cecilia J (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S004100
Reexamination Certificate
active
08034768
ABSTRACT:
The present invention includes methods of treatment and compositions for treating diseases related to the activity of a histone deacetylase in a subject by administering to the subject an effective amount of a modified FK228 compound comprising an amino acid conjugate which constitutes an amino thiol, a hydroxy thiol, a dithiol, or a hydroxamic acid, instead of a hydroxy-mercapto-heptenoic acid moiety in FK228.
REFERENCES:
patent: 7041639 (2006-05-01), Skov
patent: 7091229 (2006-08-01), Georges et al.
patent: 7098186 (2006-08-01), Nagai et al.
patent: 7314862 (2008-01-01), Naoe et al.
patent: 2005/0176686 (2005-08-01), Maurer et al.
patent: 2005/0209134 (2005-09-01), Nagai et al.
patent: 2006/0128660 (2006-06-01), Rajski et al.
patent: 2006/0135413 (2006-06-01), Naoe et al.
patent: 2006/0269559 (2006-11-01), Jackson et al.
patent: 2007/0117848 (2007-05-01), Puerta et al.
patent: 2007/0129290 (2007-06-01), Or et al.
patent: 2007/040522 (2007-04-01), None
Ahn, J.-M., et al., “Peptidomimetics and peptide backbone modifications.” Mini-Reviews in Medicinal Chemistry (2002), 2:463-473.
Ahn, S. H., et al., “Sterile 20 kinase phosphorylates histone H2B at serine10 during hydrogen peroxide induced apoptosis in S. cerevisiae.” Cell (2005), 120:25-36.
Cao, H., et al., “Induction of human gamma globin gene expression by histone deacetylase inhibitors.” Blood (2004), 103:701-709.
Di Maro, S., et al., “Development of an Efficient Solid-Phase Synthetic Methodology to Construct a Combinatorial Library of a Potent HDAC Inhibitor,” (Abstract) 2007 APS Symposium.
Furumai, R., et al., “FK228 (Depsipeptide) as a Natural Prodrug That Inhibits Class I Histone Deacetylases,” Cancer Research (2002), 62:4916-4921.
Holbert, M., et al., “Structure and activity of enzymes that remove histone modifications,” Curr Op Struc Biol (2005), 15:673-680.
Liu, T., et al., “Histone deacetylase inhibitors: Multifunctional anticancer agents,” Cancer Treatment Reviews (2006), 32:157-165.
Monneret, C., “Histone deacetylase inhibitors,” Eur J Med Chem (2005), 40:1-13.
Peedicayil, J. “Epigenetic therapy—a new development in pharmacology.” Indian J. Med. Res. (2006), 123:17-24.
Somoza, J. R., et al., “Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases.” Structure (2004), 12:1325-1334.
Vannini, A., et al., “Crystal structure of a eukaryotic Zn-dependent histone deacetylase, human HDAC8, complexed with a hydroxamide acid inhibitor.” Proc. Natl. Acad. Sci. U.S.A. (2004), 101:15064-15069.
Wang, D-F., et al., “Toward Selective Histone Deacetylase Inhibitor Design: Homology Modeling, Docking Studies, and Molecular Dynamics Simulations of Human Class I Histone Deacetylases,” J Med Chem (2005), 48:6936-6947.
Yamada, H., et al., “Depsipeptide-resistant KU812 cells show reversible P-glycoprotein expression:hyper-acetylated histones, and modulated gene expression profile.” Leukemia Res. (2006), 30:723-734.
International Search Report and Written Opinion for PCT/US2008/067924 dated Sep. 11, 2008.
Board of Regents , The University of Texas System
Chalker Flores LLP
Flores Edwin S.
Gudibande Satyanarayana
Singleton Chainey P.
LandOfFree
Composition and method for the treatment of diseases... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition and method for the treatment of diseases..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition and method for the treatment of diseases... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4282880